Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of HEV-239 (Hecolin) in Healthy US Adults
NCT03827395Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Apr 2019
- Primary completion
- Aug 2020
- Modality
- Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in hepatitis E (HEV) comparing HEV-239 with Placebo (2 arms). Primary endpoints: Number of Participants With Solicited Local Reactogenicity Events, Number of Participants With Solicited Systemic Reactogenicity Events and 4 more. Started Apr 2019; status: completed.
02
Drugs
HEV 239
03
Conditions
hepatitis E (HEV)
Beyond the preview
Go deeper on NCT03827395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03827395.